Oncology
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer
While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.
Mirati’s Adagrasib Challenger Fails To Differentiate Itself From Amgen’s Lumakras
While adagrasib showed decent efficacy in its pivotal study in NSCLC, some analysts said its inability to outperform Amgen’s Lumakras and its safety profile leave little room for differentiation.
ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics
Roche looks set to gain first and second place in the race to bring CD3Xcd20s to market – but Genmab and AbbVie have a strong challenger.
Could CAR-Ts Roll Into The Community Setting?
While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space.
High Hopes For Heidelberg Pharma With Huadong Onboard
CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.
SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.
Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.
Five Late-Breaking Studies To Look Out For At ASCO
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.
Boryung’s Two-Track R&D Strategy: Innovative Drugs And Cash Cows
Boryung’s chief technology officer outlines R&D strategy to move forward as a Korea-based global pharma firm and how domestic pharmas are juggling new drug development and generating cash cows.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.